Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

"Creating a multiplex assay of variant effects for proprotein convertase subtilisin/kexin type 9, an enzyme implicated in coronary artery disease"

EF 2019-20

Résumé
"The risk of coronary artery disease is increased by a high amount of circulating low density lipoprotein (LDL). LDL is cleared from the bloodstream by low density lipoprotein receptors (LDLR) expressed on the surface of hepatocytes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the degradation of LDLR. Gain-of-function PCSK9 mutations decrease the amount of LDLR available to bind LDL, therefore increasing coronary artery disease risk. As most clinical interpretations of missense variants are variants of unknown significance, I propose to create a variant effect map for PCSK9 using a pooled oligo-guided codon mutagenesis approach developed in the Roth lab. I will integrate a library of PCSK9 variants into HeLa cells and use flow cytometry to bin variants by level of LDLR expression. I can then measure the allele frequency of each PCSK9 variant in each bin. A more deleterious PCSK9 variant is expected to be found at a lower frequency in high-LDLR cells. Using machine learning, I will refine the results to map PCSK9 variants onto a multiplex assay of variant effects. I hypothesize that in creating a multiplex assay of variant effects for PCSK9, functional scores given to PCSK9 variants will aid in interpreting clinical variants of PCSK9. The information from the multiplex assay of variant effects for PCSK9 will be useful for interpreting variants of unknown significance. Early detection of PCSK9 risk variants in patients will decrease the rate of coronary artery disease in the population through advising increased LDL surveillance and lifestyle modifications."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428697
Name
Axakova Anna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
"Creating a multiplex assay of variant effects for proprotein convertase subtilisin/kexin type 9, an enzyme implicated in coronary artery disease"
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiovascular Disease; Cholesterol Synthesis Pathway; Gain-Of-Function Mutations; Loss-Of-Function Mutations; Low Density Lipoprotein Pathway; Machine Learning; Multiplexed Assays Of Variant Effect; Personalized Medicine; Variant Effect Map; Variants Of Unknown Significance
Abstract
"The risk of coronary artery disease is increased by a high amount of circulating low density lipoprotein (LDL). LDL is cleared from the bloodstream by low density lipoprotein receptors (LDLR) expressed on the surface of hepatocytes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the degradation of LDLR. Gain-of-function PCSK9 mutations decrease the amount of LDLR available to bind LDL, therefore increasing coronary artery disease risk. As most clinical interpretations of missense variants are variants of unknown significance, I propose to create a variant effect map for PCSK9 using a pooled oligo-guided codon mutagenesis approach developed in the Roth lab. I will integrate a library of PCSK9 variants into HeLa cells and use flow cytometry to bin variants by level of LDLR expression. I can then measure the allele frequency of each PCSK9 variant in each bin. A more deleterious PCSK9 variant is expected to be found at a lower frequency in high-LDLR cells. Using machine learning, I will refine the results to map PCSK9 variants onto a multiplex assay of variant effects. I hypothesize that in creating a multiplex assay of variant effects for PCSK9, functional scores given to PCSK9 variants will aid in interpreting clinical variants of PCSK9. The information from the multiplex assay of variant effects for PCSK9 will be useful for interpreting variants of unknown significance. Early detection of PCSK9 risk variants in patients will decrease the rate of coronary artery disease in the population through advising increased LDL surveillance and lifestyle modifications."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Axakova, Anna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~